MedPath

Multicenter retrospective analysis of Elotuzumab, lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma

Not Applicable
Conditions
multiple myeloma
Registration Number
JPRN-UMIN000042502
Lead Sponsor
Japan Red Cross Medical Center
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up continuing
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

Cases received ERd as clinical trial.

Study & Design

Study Type
Others,meta-analysis etc
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
overall response rate, very good partial response rate, complete response rate
Secondary Outcome Measures
NameTimeMethod
progression free survival overall survival time to nexuses treatment
© Copyright 2025. All Rights Reserved by MedPath